N
Nathan R. Foster
Researcher at Mayo Clinic
Publications - 167
Citations - 6932
Nathan R. Foster is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 34, co-authored 148 publications receiving 5857 citations. Previous affiliations of Nathan R. Foster include University of Rochester & North Central Cancer Treatment Group.
Papers
More filters
Journal ArticleDOI
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent,Silvia Marsoni,Geneviève Monges,Stephen N. Thibodeau,Roberto Labianca,Stanley R. Hamilton,Amy J. French,Brian Kabat,Nathan R. Foster,Valter Torri,Christine Ribic,Axel Grothey,Malcolm J. Moore,Alberto Zaniboni,Jean Francois Seitz,Frank A. Sinicrope,Steven Gallinger +16 more
TL;DR: Data support MMR status assessment for patients being considered for FU therapy alone and consideration of MMR status in treatment decision making and patient stratification by MMR status may provide a more tailored approach to colon cancer adjuvant therapy.
Journal ArticleDOI
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma.
Michael B. Farnell,Randall K. Pearson,Michael G. Sarr,Eugene P. DiMagno,Lawrence J. Burgart,Tamela R. Dahl,Nathan R. Foster,Daniel J. Sargent +7 more
TL;DR: Both the decrement in quality of life and similar studies showing no survival difference make PD/ELND unattractive for further prospective investigation.
Journal ArticleDOI
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope,Nathan R. Foster,Stephen N. Thibodeau,Silvia Marsoni,Geneviève Monges,Roberto Labianca,Greg Yothers,Carmen J. Allegra,Malcolm J. Moore,Steven Gallinger,Daniel J. Sargent +10 more
TL;DR: Patients with dMMR Colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers, and a subset analysis suggested that any treatment benefit was restricted to suspected germline vs sporadic tumors.
Journal ArticleDOI
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Brigette B.Y. Ma,Wan-Teck Lim,Boon Cher Goh,Edwin P. Hui,Kwok Wai Lo,Adam Pettinger,Nathan R. Foster,Jonathan W. Riess,Mark Agulnik,Alex Y. Chang,Akhil Chopra,Julie A. Kish,Christine H. Chung,Douglas Adkins,Kevin J. Cullen,Barbara J. Gitlitz,D. Lim,Ka Fai To,K.C. Allen Chan,Y.M. Dennis Lo,Ann D. King,Charles Erlichman,Jun Yin,Brian A. Costello,Anthony T.C. Chan +24 more
TL;DR: Nivolumab has promising activity in NPC and the 1-year overall survival rate compares favorably with historic data in similar populations and the biomarker results were hypothesis generating and validation in larger cohorts is needed.
Journal ArticleDOI
Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma
Frank A. Sinicrope,Rafaela L. Rego,Stephen M. Ansell,Keith L. Knutson,Nathan R. Foster,Daniel J. Sargent +5 more
TL;DR: In this paper, the authors investigated whether the intratumoral densities of FoxP3 + and effector CD3 + lymphocytes are associated with prognosis of patients with colon cancer.